NCT00851734View on ClinicalTrials.gov

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 31, 2009

Study Completion Date

April 30, 2009

Conditions
Keratoconjunctivitis Sicca
Interventions
DRUG

voclosporin ophthalmic solution

0.02%, 0.2% t.i.d. or b.i.d.

Trial Locations (1)

19428

Product Investigations, Conshohocken

Sponsors
All Listed Sponsors
lead

Lux Biosciences, Inc.

INDUSTRY